CompletedNot Applicable

A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022

93,481 participantsStarted 2000-12-01

Plain-language summary

Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). This study focus on the mortality risk analysis for GI carcinoids due to data insufficiency in the literature.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients diagnosed with gastrointestinal carcinoid tumor * from 2000-2022 * histologically confirmed Exclusion Criteria: * death certificate only and autopsy only patients * patients with unknown age data.

What they're measuring

The standardized mortality ratio of GI carcinoid tumors

Timeframe: 2000-2022

Trial details

NCT IDNCT07317713

SponsorSuez Canal University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-30

View on ClinicalTrials.gov More Carcinoid Tumor trials